Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition

Details for Australian Patent Application No. 2005313312 (hide)

Owner Solvay Pharmaceuticals B.V.

Inventors Hesselink, Mayke B.; Kruse, Cornelis G.; Van Vliet, Bernard J.; Terpstra, JanWillem; McCreary, Andrew C.; Feenstra, Roelof W.; Stoit, Axel; Van Scharrenburg, Gustaaf J.M.; Pras-Raves, Maria L.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005313312

PCT Pub. Number WO2006/061379

Priority 60/634,074 08.12.04 US; 04106394.2 08.12.04 EP

Filing date 6 December 2005

Wipo publication date 15 June 2006

International Classifications

A61K 31/423 (2006.01) - condensed with carbocyclic rings

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

5 July 2007 PCT application entered the National Phase

  PCT publication WO2006/061379 Priority application(s): WO2006/061379

3 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005313313-Substituted imidazo[4,5-b]pyridines as inhibitors of gastric acid secretion

2005313311-Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition